Legacy Financial Advisors Inc. Invests $295,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Legacy Financial Advisors Inc. acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, HoldingsChannel reports. The fund acquired 3,198 shares of the biopharmaceutical company’s stock, valued at approximately $295,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. HHM Wealth Advisors LLC lifted its stake in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares during the last quarter. YANKCOM Partnership bought a new position in Gilead Sciences during the fourth quarter valued at about $28,000. Decker Retirement Planning Inc. bought a new stake in shares of Gilead Sciences during the 4th quarter worth about $29,000. Crews Bank & Trust acquired a new position in shares of Gilead Sciences during the 4th quarter valued at about $31,000. Finally, Stephens Consulting LLC raised its stake in shares of Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 260 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 302,785 shares of company stock worth $30,503,250 over the last three months. 0.16% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on GILD. Piper Sandler upped their target price on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and raised their price target for the company from $80.00 to $120.00 in a research report on Tuesday, February 18th. Oppenheimer upped their price target on Gilead Sciences from $115.00 to $132.00 and gave the stock an “outperform” rating in a report on Tuesday, March 4th. DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price objective on the stock in a research note on Thursday, February 13th. Finally, Royal Bank of Canada upped their target price on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 12th. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $105.12.

Gilead Sciences Trading Up 2.2 %

GILD opened at $103.63 on Friday. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The firm has a 50-day moving average price of $108.34 and a two-hundred day moving average price of $96.79. The stock has a market capitalization of $129.04 billion, a PE ratio of 280.08, a PEG ratio of 0.71 and a beta of 0.32. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Friday, March 14th were issued a $0.79 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend was Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 3.05%. Gilead Sciences’s dividend payout ratio (DPR) is currently 854.05%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.